SRSophie T. Rouvray

Sophie T. Rouvray

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sophie T. Rouvray has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interferon-γ and IL-27 positively regulate type 1 regulatory T cell development during adaptive tolerance

    by David A.J. Lecky, Lozan Sheriff, Sophie T. Rouvray, Lorna S. George, Alastair Copland, Rebecca A. Drummond, David C. Wraith, David Bending


  • Open Access

    Interferon-γ and IL-27 positively regulate type 1 regulatory T-cell development during adaptive tolerance

    by David A.J. Lecky, Lozan Sheriff, Sophie T. Rouvray, Lorna S. George, Rebecca A. Drummond, David C. Wraith, David Bending

    Summary: Strong T-cell receptor (TCR) and IL-27 signalling influence type-1 regulatory (Tr1) T-cell development but whether other signals determine their differentiation is unclear. Utilising Tg4 TCR transgenic mice we established a model for rapid Tr1 cell induction. A single high dose of [4Y]-MBP peptide drove the differentiation of Il10 + T-cells with bona fide Tr1 cell protein and mRNA signatures. Kinetic transcriptional analysis revealed that the Tr1 cell module was transient and preceded by a burst of Ifng transcription in CD4+ T-cells. Neutralisation of IFNγ reduced Tr1 cell frequency and strong TCR signalling markers, which was correlated with reduced macrophage activation. Antibody depletion experiments inferred that T-cells – but not NK cells – provided the relevant source of IFNγ. Additionally, we show that blocking IL-27 in combination with IFNγ neutralisation additively reduced Tr1 cell frequency in vivo . These findings reveal that during strong tolerogenic TCR signalling IFN-γ has a non-redundant regulatory role in augmenting the differentiation of Tr1 cells in vivo .

  • Open Access

    Lag3 and PD-1 pathways regulate NFAT-dependent TCR signalling programmes during early CD4 + T cell activation

    by Lozan Sheriff, Alastair Copland, David A.J. Lecky, Reygn Done, Lorna S George, Emma K. Jennings, Sophie Rouvray, Thomas A.E. Elliot, Elizabeth S. Jinks, Lalit Pallan, et al.

    Summary: Lag3 and PD-1 are immune checkpoints that regulate T cell responses and are current immunotherapy targets. Yet how they function to control early CD4 + T cell activation remains unclear. Here, we show that the PD-1 and Lag3 pathways exhibit layered control of the early CD4 + T cell activation process, with the effects of Lag3 more pronounced in the presence of PD-1 pathway co-blockade (CB). RNA-sequencing revealed that CB drove an early NFAT-dependent transcriptional profile, including promotion of ICOS hi T follicular helper (Tfh) cell differentiation. NFAT pathway inhibition abolished CB-induced upregulation of NFAT-dependent co-receptors ICOS and OX40, whilst unaffecting the NFAT-independent gene Nr4a1 . Mechanistically, Lag3 and PD-1 pathways functioned additively to regulate the duration of T cell receptor (TCR) signals during CD4 + T cell re-activation. Our data therefore reveal that PD-1 and Lag3 pathways converge to additively regulate TCR signal duration and NFAT-dependent transcriptional activity during early CD4 + T cell re-activation. Highlights: PD-1 and Lag3 pathways exhibit layered control of early CD4 + T cell activation Their co-blockade enhances NFAT-dependent TCR transcriptional programmes Inhibition of NFAT signalling reverses the functional effects of PD-1 and Lag3 co-blockade Mechanistically, PD-1 and Lag3 function to additively regulate TCR signal duration during re-activation of CD4 + T cells